About

AtaiBeckley is a biopharmaceutical company that develops rapid-acting mental-health therapies. Its pipeline includes an intranasal mebufotenin benzoate candidate (BPL-003) for treatment-resistant depression, a DMT buccal film, and an oral R-MDMA compound . The company conducts clinical trials and drug development in neuropsychiatric conditions.

Position in the VCSift Database

  • 4,609 investors in VCSift focus on the biotech sector.
  • 1,517 investors are based in Berlin, Berlin, Germany.

Data sourced from 410,343 investor profiles. Updated July 2026.

Investment Focus

Sectors
biotech

Contact Information

in••••@ataibeckley.com
linkedin.com/in/••••••••

Unlock contact details with a VCSift subscription

Unlock Contact

Already subscribed? Log in

Find more investors like AtaiBeckley

Search Investors